Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms

doi:10.1385/IR:36:1:33

Review

. 2006;36(1-3):33-41.

doi: 10.1385/IR:36:1:33.

Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms

Anthony G Brickner¹

Affiliations

PMID: 17337764
DOI: 10.1385/IR:36:1:33

Review

Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms

Anthony G Brickner. Immunol Res. 2006.

. 2006;36(1-3):33-41.

doi: 10.1385/IR:36:1:33.

Author

Anthony G Brickner¹

Affiliation

¹ Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA. bricknerag@upmc.edu

PMID: 17337764
DOI: 10.1385/IR:36:1:33

Abstract

Minor histocompatibility antigens (mHAgs) are a diverse collection of major histocompatibility complex (MHC)-bound peptides that play a critical role in the induction of detrimental graft-versus-host disease (GVHD) or the development of beneficial graft-versustumor (GVT) effects after allogeneic hematopoietic stem cell transplantation. mHAgs are a consequence of allelic polymorphism that translates to disparity in MHC-presented peptide epitopes between transplant donor and recipient. This donor/recipient allelic disparity can range from infinitesimal amino side chain differences between MHC-presented peptides, to profound structural polymorphisms in genes and proteins that can nullify transcription or translation of one allelic variant and result in the complete abrogation of its presentation by MHC.

PubMed Disclaimer

Cited by

Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
Feng X, Hui KM, Younes HM, Brickner AG. Feng X, et al. Trends Immunol. 2008 Dec;29(12):624-32. doi: 10.1016/j.it.2008.09.004. Epub 2008 Oct 25. Trends Immunol. 2008. PMID: 18952501 Free PMC article. Review.
Clinical impact of H-Y alloimmunity.
Popli R, Sahaf B, Nakasone H, Lee JY, Miklos DB. Popli R, et al. Immunol Res. 2014 May;58(2-3):249-58. doi: 10.1007/s12026-014-8514-3. Immunol Res. 2014. PMID: 24781195 Free PMC article. Review.
Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation.
Story CM, Wang T, Bhatt VR, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LA, Marsh SGE, Gadalla SM, Schetelig J, Mytilineos J, Miklos D, Waller EK, Kuxhausen M, Spellman S, Lee S, Paczesny S, Lansford JL, Vincent BG, Riches ML, Armistead PM; Center for International Blood and Marrow Transplant Research Immunobiology Working Committee. Story CM, et al. Transplant Cell Ther. 2021 Jul;27(7):591-599. doi: 10.1016/j.jtct.2021.04.003. Epub 2021 Apr 18. Transplant Cell Ther. 2021. PMID: 33882342 Free PMC article.
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor.
Cattina F, Bernardi S, Mantovani V, Toffoletti E, Santoro A, Pastore D, Martino B, Console G, Martinelli G, Malagola M. Cattina F, et al. Hematol Rep. 2017 Sep 26;9(3):7051. doi: 10.4081/hr.2017.7051. eCollection 2017 Sep 26. Hematol Rep. 2017. PMID: 29071050 Free PMC article. No abstract available.
Transgenic HA-1-Specific CD8⁺ T-Lymphocytes Selectively Target Leukemic Cells.
Pilunov A, Romaniuk DS, Shmelev A, Sheetikov S, Gabashvili AN, Khmelevskaya A, Dianov D, Zornikova K, Shakirova NT, Vagida M, Bogolyubova A, Efimov GA. Pilunov A, et al. Cancers (Basel). 2023 Mar 3;15(5):1592. doi: 10.3390/cancers15051592. Cancers (Basel). 2023. PMID: 36900382 Free PMC article.

See all "Cited by" articles

References

1. Nat Rev Cancer. 2004 May;4(5):371-80 - PubMed
1. N Engl J Med. 1979 May 10;300(19):1068-73 - PubMed
1. Mol Immunol. 2002 Oct;39(3-4):127-37 - PubMed
1. Biol Blood Marrow Transplant. 2004 Apr;10(4):215-23 - PubMed
1. J Immunol. 2000 Mar 1;164(5):2807-14 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Nat Rev Cancer. 2004 May;4(5):371-80 - PubMed

[2] Nat Rev Cancer. 2004 May;4(5):371-80 - PubMed

[3] N Engl J Med. 1979 May 10;300(19):1068-73 - PubMed

[4] N Engl J Med. 1979 May 10;300(19):1068-73 - PubMed

[5] Mol Immunol. 2002 Oct;39(3-4):127-37 - PubMed

[6] Mol Immunol. 2002 Oct;39(3-4):127-37 - PubMed

[7] Biol Blood Marrow Transplant. 2004 Apr;10(4):215-23 - PubMed

[8] Biol Blood Marrow Transplant. 2004 Apr;10(4):215-23 - PubMed

[9] J Immunol. 2000 Mar 1;164(5):2807-14 - PubMed

[10] J Immunol. 2000 Mar 1;164(5):2807-14 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms

Affiliation

Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms

Author

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials